Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes

Abstract Background and aims Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 2017-09, Vol.264, p.108-114
Hauptverfasser: Samman Tahhan, Ayman, Hayek, Salim, Sandesara, Pratik, Hajjari, Jamal, Hammadah, Muhammad, O'Neal, Wesley T, Kelli, Heval M, Alkhoder, Ayman, Ghasemzadeh, Nima, Ko, Yi-An, Aida, Hiroshi, Gafeer, Mohamad Mazen, Abdelhadi, Naser, Hosny, Kareem, Patel, Keyur, Arya, Shipra, Reiser, Jochen, Vaccarino, Viola, Sperling, Laurence, Quyyumi, Arshed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background and aims Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study. Methods SuPAR levels were measured in 5810 patients (mean age 63 years, 63% male, 77% with obstructive coronary artery disease [CAD]) undergoing cardiac catheterization. The presence of PAD (n = 967, 17%) was classified as carotid (36%), lower/upper extremities (30%), aortic (15%) and multisite disease (19%). Multivariable logistic and Cox regression models were used to determine independent predictors of prevalent PAD and outcomes including all-cause death, cardiovascular death and PAD-related events after adjustment for age, gender, race, body mass index, smoking, diabetes, hypertension, hyperlipidemia, renal function, heart failure history, and obstructive CAD. Results Plasma suPAR levels were 22.5% ( p  
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2017.06.019